Clinical trials: Intravenous
Healthy
IV Dosage Form of LCB01-0371 Phase I Study in Healthy Male Volunteers
Primary - To investigate the Pharmacokinetics, Safety, and Tolerability of Intravenous dosage form of LCB01-0371 comparing to oral dosage in Healthy Male Volunteers Secondary To investigate the absolute bio availability of…
- Trial name
- NCT02882789
- Testing
- LCB01-0371, LCB01-0371 400mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- LigaChem Biosciences, Inc.
Iron Deficiency Anemia
Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)
The purpose of this study is to monitor and quality assure the efficacy and safety of Monofer® in a broad patient population when Monofer® is used according to the Monofer® label (SPC) in current practice and where standard…
- Trial name
- NCT01900197
- Testing
- 10% Iron Isomaltoside 1000
- Where
- Denmark
- Volunteers
- 391 people
- Sponsor
- Pharmacosmos A/S
RSV Illness in ≤12 Months of Participants
A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness
The primary objective of this study is to describe the effect of a single dose of medication compared to placebo in the upper respiratory tract in previously healthy children less than or equal to 12 months of age who are…
- Trial name
- NCT00421304
- Testing
- Motavizumab
- Where
- 35 sites in United States, Australia and 3 more
- Volunteers
- 118 people
- Sponsor
- MedImmune LLC
Melanoma
A Study of Intravenous INO-1001 Plus Oral Temozolomide to Evaluate Tolerability, Safety, and Pharmacokinetics in Patients With Melanoma
This is a prospective, open-label, non-randomized, multicenter study in adults, aged eighteen (18) or older, with newly-diagnosed or recurrent unresectable Stage III or Stage IV melanoma.
- Trial name
- NCT00272415
- Testing
- INO-1001, temozolomide
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Prostatic Neoplasms
A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer
The purpose of this study is to determine the safety of docetaxel and CNTO 328 when given together as a treatment. The second goal of this study is to determine if a combination of docetaxel and CNTO 328 has an effect on prostate…
- Trial name
- NCT00401765
- Testing
- CNTO 328, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Centocor, Inc.
Influenza
A Study of Intravenous Tamiflu (Oseltamivir) in Children With Influenza
This open-label study will assess the pharmacokinetics/pharmacodynamics and safety of intravenous (iv) Tamiflu (oseltamivir) in 3 cohorts of children, aged 6-12, 3-5 and 1-2 years, with influenza infection.
- Trial name
- NCT01033734
- Testing
- oseltamivir [Tamiflu]
- Where
- 38 sites in United States, Israel and 1 more
- Volunteers
- 8 people
- Sponsor
- Hoffmann-La Roche
Pharmacokinetics
A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents
This study is designed to collect additional pharmacokinetic and safety data of voriconazole in immunocompromised adolescents receiving intravenous and oral voriconazole.
- Trial name
- NCT00556998
- Testing
- Voriconazole
- Where
- 9 sites in United States
- Volunteers
- 26 people
- Sponsor
- Pfizer
Healthy
Bioequivalence of Two Formulations of Meropenem Intravenous Injection
A randomized, single-dose, two-way crossover study to evaluate bioequivalence of two formulations of meropenem (meropenem intravenous injection 0.5 g) after intravenous infusion in healthy volunteers.
- Trial name
- NCT02344563
- Testing
- Meropem, Mepem
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Yung Shin Pharm. Ind. Co., Ltd.
Hypereosinophilia, Hypereosinophilic Syndrome
Intravenous Mepolizumab In Subjects With Hypereosinophilic Syndromes (HES)
Hypereosinophilic syndrome (HES) is a rare disease with broad clinical signs and symptoms which is diagnosed based on a persistent blood eosinophil count of greater than 1500 cells, various end-organ damages (including skin…
- Trial name
- NCT00086658
- Testing
- mepolizumab
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 86 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Follicular
A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular Lymphoma
This 2 stage study will compare the pharmacokinetics and safety profile of subcutaneous and intravenous rituximab in participants with follicular lymphoma.
- Trial name
- NCT00930514
- Testing
- Rituximab
- Where
- 62 sites in Argentina, Australia and 20 more
- Volunteers
- 281 people
- Sponsor
- Hoffmann-La Roche
Healthy
Study to Determine Tolerability After Intravenous Administration of BIBN 4096 BS in Healthy Male and Female Volunteers
The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single intravenous administration of increasing doses in healthy male and female volunteers
- Trial name
- NCT02198352
- Testing
- BIBN 4096 BS - in single rising doses
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Lung Cancer
The Comparative Study on Rh-Endostatin (Endostar®) Continuous Intravenous Infusion and Routine i.v in Combination With GP Regimens for Phase III B/IV Squamous Cell Lung Cancer and Biological Markers Exploration.
Endostar is a anti-angiogenesis product and has been launched in China . The efficacy and safety have been defined. However, the compliance is unsatisfactory since routine i.v of Endostar is needed for 3 to 4 hours daily during…
- Trial name
- NCT02283476
- Testing
- Endostar continuous intravenous infusion, Endostar routine intravenous infusion, Gemcitabine
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Acute Ischemic Stroke
A Phase 2a Study to Evaluate the Dose-response, Safety, Tolerability, Efficacy, and Population Pharmacokinetics of Intravenous NTS-521 Infusions in the Early Recovery Treatment From Acute Ischemic Stroke
This is a trial to evaluate the safety and effect of three intravenous (IV) doses of NTS-521 for the early recovery treatment of acute ischemic stroke (AIS). Participants will be followed for 90 days.
- Trial name
- ACT-IVATE (NCT07742098)
- Testing
- NTS-521
- Volunteers
- 140 people
- Sponsor
- NeuroTrauma Sciences, LLC
Hepatitis B
Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection
The purpose of this study is to evaluate the safety and pharmacokinetics of healthy male adults when subjects are repeatedly administered GC1102 (Hepabig_Gene) through intravenous injection.
- Trial name
- NCT01606163
- Testing
- GC1102, JW normal saline
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Green Cross Corporation
Infiltration, Extravasation
Monitoring the Peripheral Intravenous Infusion Site for Infiltration and Extravasation
The purpose of this study to to monitor the peripheral intravenous (PIV) site on subjects receiving continuous IV fluids for infiltration and extravasation events.
- Conditions
- Infiltration, Extravasation, IV Infiltration, IV Extravasation
- Trial name
- NCT01476293
- Where
- United States
- Volunteers
- 139 people
- Sponsor
- ivWatch, LLC
Congenital Bleeding Disorder, Congenital FXIII Deficiency
Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency
This trial is conducted in Europe and United States of America (USA). The aim of this clinical trial is to investigate the pharmacokinetics (at which rate the substance is distributed and eliminated from the body) and the safety…
- Trial name
- mentor™4 (NCT01230021)
- Testing
- catridecacog
- Where
- 10 sites in United States, Israel and 1 more
- Volunteers
- 6 people
- Sponsor
- Novo Nordisk A/S
Thrombocytosis, Iron-Deficiency Anemia
Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD)
The aim of this study is to show the benefits for patients, with a high platelet count, iron deficiency and IBD, receiving intravenous iron therapy.
- Trial name
- NCT00882414
- Testing
- FERINJECT® (Ferric carboxymaltose)
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Vifor Pharma
Ulcerative Colitis, Crohn's Disease
Vedolizumab Subcutaneous (SC) Versus Intravenous (IV) in Ulcerative Colitis or Crohn's Disease
The purpose of this study is to assess the bioavailability and pharmacokinetics (PK) of multiple doses of vedolizumab subcutaneous (SC) compared to vedolizumab intravenous (IV).
- Trial name
- NCT02913508
- Testing
- Vedolizumab intravenous injection, Vedolizumab subcutaneous injection
- Sponsor
- Takeda
Iron Deficiency Anemia
Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia
The purpose of this study is to confirm the non-inferiority of Z-213 compared to Saccharated Ferric Oxide using the maximum change in Hb from baseline over 12 weeks in patients with Iron-deficiency Anemia (IDA)
- Trial name
- NCT02731534
- Testing
- Z-213, Saccharated Ferric Oxide
- Where
- Japan
- Volunteers
- 238 people
- Sponsor
- Zeria Pharmaceutical
Multiple Myeloma
Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant
MBL deficient patients enrolled in this protocol are scheduled to be treated with melphalan-based high-dose chemotherapy followed by autologous hematopoietic stem cell transplant (HSCT) for their multiple myeloma.
- Trial name
- NCT00388999
- Testing
- Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.